Texas Permanent School Fund lessened its holdings in shares of Mylan NV (NASDAQ:MYL) by 3.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 96,093 shares of the company’s stock after selling 3,314 shares during the quarter. Texas Permanent School Fund’s holdings in Mylan were worth $1,901,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Advisory Services Network LLC raised its stake in Mylan by 170.0% during the 2nd quarter. Advisory Services Network LLC now owns 1,520 shares of the company’s stock worth $29,000 after buying an additional 957 shares during the period. NuWave Investment Management LLC raised its stake in shares of Mylan by 1,111.0% in the 2nd quarter. NuWave Investment Management LLC now owns 2,192 shares of the company’s stock valued at $42,000 after purchasing an additional 2,011 shares during the period. Rational Advisors LLC raised its stake in shares of Mylan by 1,111.0% in the 2nd quarter. Rational Advisors LLC now owns 2,192 shares of the company’s stock valued at $42,000 after purchasing an additional 2,011 shares during the period. Steward Partners Investment Advisory LLC raised its stake in shares of Mylan by 92.9% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 2,367 shares of the company’s stock valued at $46,000 after purchasing an additional 1,140 shares during the period. Finally, CSat Investment Advisory L.P. raised its stake in shares of Mylan by 258.9% in the 2nd quarter. CSat Investment Advisory L.P. now owns 2,835 shares of the company’s stock valued at $54,000 after purchasing an additional 2,045 shares during the period. 84.46% of the stock is currently owned by institutional investors and hedge funds.
In other news, Director Sjoerd S. Vollebregt acquired 10,000 shares of the stock in a transaction on Tuesday, August 13th. The stock was acquired at an average cost of $19.11 per share, for a total transaction of $191,100.00. Following the completion of the transaction, the director now directly owns 18,258 shares in the company, valued at $348,910.38. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Melina E. Higgins acquired 20,000 shares of the stock in a transaction on Thursday, August 15th. The shares were purchased at an average price of $17.68 per share, with a total value of $353,600.00. Following the completion of the transaction, the director now owns 33,120 shares of the company’s stock, valued at $585,561.60. The disclosure for this purchase can be found here. 0.81% of the stock is currently owned by insiders.
Shares of NASDAQ MYL opened at $17.61 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.43 and a quick ratio of 0.77. Mylan NV has a fifty-two week low of $16.63 and a fifty-two week high of $37.06. The business has a 50-day moving average of $19.03 and a 200-day moving average of $19.74. The stock has a market capitalization of $9.18 billion, a price-to-earnings ratio of 3.84, a PEG ratio of 0.84 and a beta of 1.75.
Mylan (NASDAQ:MYL) last released its quarterly earnings results on Tuesday, November 5th. The company reported $1.17 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.03. Mylan had a net margin of 0.42% and a return on equity of 18.80%. The company had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $3.01 billion. During the same period in the previous year, the business earned $1.25 earnings per share. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. On average, sell-side analysts expect that Mylan NV will post 4.29 EPS for the current year.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
See Also: CBOE Russell 2000® Volatility Index
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.